doi: 10.5582/ddt.2020.01017.
Epub 2020 Mar 26.
Facts and reflections on COVID-19 and anti-hypertensives drugs
Affiliations
- PMID: 32213760
- DOI: 10.5582/ddt.2020.01017
Item in Clipboard
Facts and reflections on COVID-19 and anti-hypertensives drugs
Drug Discov Ther.
.
Free article
Abstract
Based on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensive drug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin II receptor blockers (e.g. losartan), many patients from South America, Central America or Spain, have stopped or intend to interrupt their treatments with these drugs. Hence, it may exist ominous consequences due to this drop out. For this reason, it is necessary to quickly warn about this situation and the risks associated with it.
Keywords: ACE; ATII-RB; Anti-hypertensive drugs; COVID-19; SARS-CoV-2.
Similar articles
-
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812. JAMA. 2020. PMID: 32208485 No abstract available.
-
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450. J Hypertens. 2020. PMID: 32195824 No abstract available.
-
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651. Med Sci Monit. 2020. PMID: 32969367 Free PMC article.
-
Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.Pol Merkur Lekarski. 2020 Jun 17;48(285):195-198. Pol Merkur Lekarski. 2020. PMID: 32564046 Review.
-
[The RAAS and SARS-CoV-2: A riddle to solve].Hipertens Riesgo Vasc. 2020 Oct-Dec;37(4):169-175. doi: 10.1016/j.hipert.2020.05.005. Epub 2020 May 27. Hipertens Riesgo Vasc. 2020. PMID: 32527699 Free PMC article. Review. Spanish.
Cited by
-
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1. Saudi Pharm J. 2020. PMID: 32905015 Free PMC article. Review.
-
Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.Korean J Intern Med. 2021 Mar;36(2):247-262. doi: 10.3904/kjim.2020.355. Epub 2020 Oct 16. Korean J Intern Med. 2021. PMID: 33617712 Free PMC article. Review.
-
Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators.Redox Biol. 2020 Sep;36:101615. doi: 10.1016/j.redox.2020.101615. Epub 2020 Jun 24. Redox Biol. 2020. PMID: 32863223 Free PMC article.
-
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.J Biomed Sci. 2021 Jan 12;28(1):9. doi: 10.1186/s12929-020-00703-5. J Biomed Sci. 2021. PMID: 33435929 Free PMC article. Review.
-
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.Molecules. 2021 Jan 25;26(3):618. doi: 10.3390/molecules26030618. Molecules. 2021. PMID: 33504092 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
